A biotech company developing bispecific antibodies for immunological and inflammatory (I&I) disorders. Bambusa Therapeutics was founded in May 2024 and has two lead programs: BBT001 and BBT002, which ...
The US Food and Drug Administration (FDA) late Friday approved a label expansion for Netherlands-based argenx’ (Euronext & Nasdaq: ARGX) Vyvgart efgartigimod alfa-fcab) and Vyvgart Hytrulo ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results